Scott Berry

Cetuximab for the Treatment of Colorectal Cancer

Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · JAMA · 2017 · 852 citations · Full text

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry et al. · Annals of Oncology · 2009 · 532 citations

Oncology, First-line Bevacizumab, Gastrointestinal Oncology +10

American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

Jeffrey Peppercorn, Thomas J. Smith, Paul R. Helft et al. · Journal of Clinical Oncology · 2011 · 523 citations

Family Medicine, Quality Of Life, Cancer Management +19